Navigation Links
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
Date:12/4/2008

IRVINE, Calif., Dec. 4 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, today announced results from the Company's recently completed Phase III clinical program of Xibrom(TM) (0.09% bromfenac sodium ophthalmic solution) QD (once-daily). The program enrolled 282 patients who underwent cataract surgery in two U.S. multi-center, randomized, double-masked, parallel-group, vehicle-controlled studies to evaluate Xibrom 0.09% dosed once daily to vehicle (placebo). The identical trials were performed under a common protocol and designated the East region trial (ER) and the West region trial (WR).

According to a preliminary analysis, integrated results for the two studies demonstrated Xibrom 0.09% QD achieved statistical significance in meeting the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. In addition, Xibrom 0.09% QD met the secondary efficacy endpoint of elimination of ocular pain one day post surgery.

When considered independently, the WR trial showed statistical significance in both the primary and secondary efficacy endpoints. The ER exhibited strong trends in both the absence of ocular inflammation and pain but did not meet statistical significance for either. The rate of patients who discontinued due to lack of efficacy in the ER was six times greater than the WR trial and a previous clinical trial utilizing the same protocol and concentration. In addition, there was a 20 percentage-point higher placebo effect for the relief of pain in the ER compared with the WR results and with previous trial experience with bromfenac ophthalmic solution. Despite the unexpected results reported for the ER Phase III study, there were strong trends in favor of statistical efficacy.

In addition, both Phase III studi
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015 ... (Troitsk) und Strand Life Sciences, weltweiter Marktführer ... Medizin, haben eine Kooperationsvereinbarung unterzeichnet. Laut Vereinbarung ... entwickeln, basierend auf NGS (Next-Generation Sequencing), für ... Formen von Epilepsie und primären Immundefizenz (PI)-Erkrankungen. ...
(Date:6/29/2015)... N.Y. and EWING, N.J. ...  (Nasdaq: CPXX ) today announced that The Leukemia ... a portion of the final payment linked to the ... lead product candidate, for the treatment of patients with ... moved forward payment of $400,000 originally attached to the ...
(Date:6/29/2015)... MOSCOW , June 29, 2015 /PRNewswire/ ... nanocenter TECHNOSPARK (Troitsk), and Strand Life Sciences, the ... personalized medicine, have signed a cooperation memorandum. According ... develop affordable tests based on next-generation sequencing (NGS) ... hereditary forms of epilepsy and primary immunodeficiency disorders ...
Breaking Medicine Technology:Das Genomic Center of Nanocenters 'Technospark' und 'Dubna', Russland und Strand Life Sciences, Indien werden gemeinsam Tests zur Diagnose von Erbkrankheiten entwickeln 2Das Genomic Center of Nanocenters 'Technospark' und 'Dubna', Russland und Strand Life Sciences, Indien werden gemeinsam Tests zur Diagnose von Erbkrankheiten entwickeln 3The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 2The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 3The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 4The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 5The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 6The Genomic Center of Nanocenters 'Technospark' and 'Dubna', Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases 2The Genomic Center of Nanocenters 'Technospark' and 'Dubna', Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases 3
(Date:6/30/2015)... ... 30, 2015 , ... Medflow, the leader in the ophthalmic ... records system from the company exclusively dedicated to helping eye care professionals for ... state-of-the-art solution combining modern cloud technology with Medflow’s proven expertise in the eye ...
(Date:6/30/2015)... ... June 30, 2015 , ... “It is never too ... SunGrubbies.com. “We are particularly interested in getting the word out to children because ... surface. We are extremely pleased with our new video which we feel ...
(Date:6/29/2015)... ... June 30, 2015 , ... The United States ... Team (KORT) as it becomes the Official Physical and Occupational Therapists of the U.S. ... Rolex Kentucky Three-Day Event presented by Land Rover. , “The USEF is pleased ...
(Date:6/29/2015)... ... June 29, 2015 , ... An upcoming documentary for public ... Earl Jones will offer a fresh perspective on conflict in sports with guest ... one of several thought leaders from around the sports industry that will discuss challenges ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one of Southern ... their newest FAA-certified medical examiner in the city of Colton . , ... seeking to obtain their physical aviation certificates. Pilots hoping to navigate airplanes, helicopters, ...
Breaking Medicine News(10 mins):Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 2Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 3Health News:KORT Physical Therapy Announces Partnership with The United States Equestrian Federation 2Health News:Dr. Marc Williams Joins SCI and In America Sports Documentary 2Health News:Dr. Marc Williams Joins SCI and In America Sports Documentary 3Health News:Healthpointe Now Offering FAA Physical Exams in San Bernardino County 2
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Feb. ... called GAD-alum to treat type 1 diabetes failed to show ... sugar disease. The researchers, however, said they felt there ... and that specific groups of people still might benefit from ...
... Feb. 2 (HealthDay News) -- ,Greater use of certain types ... explain why black children,s risk of ischemic stroke dropped significantly ... in stroke-related deaths between black and white children also fell ... 74 percent more likely to die of ischemic stroke than ...
... By Alan Mozes HealthDay Reporter , THURSDAY, ... are exposed to might play a part in determining your ... about how sun may be bad for us, in terms ... an associate professor of biostatistics at the University of Alabama ...
... is associated with a loss of alcohol,s protective effect against ... increase of coronary risk among binge drinkers. ... the Danish National Cohort Study in 1994, 2000, and 2005 ... of IHD or all-cause mortality among "light-to-moderate" drinkers: (up to ...
... Mayo Clinic researchers have found that multiple exposures to ... rates of attention-deficit/hyperactivity disorder (ADHD) . Children exposed ... than double the incidence of ADHD than children who had ... Clinic pediatric anesthesiologist and investigator on the observational study. ...
... , WEDNESDAY, Feb. 1 (HealthDay News) -- ... good, it reduces inflammation in muscles at the cellular ... promote the growth of new mitochondria in skeletal muscle. ... the Buck Institute for Research on Aging and McMaster ...
Cached Medicine News:Health News:Type 1 Diabetes Treatment Disappoints in Trial 2Health News:Type 1 Diabetes Treatment Disappoints in Trial 3Health News:Efforts to Reduce Stroke in Kids With Sickle Cell Working: Study 2Health News:Lack of Sunlight May Raise Stroke Risk 2Health News:The effect of occasional binge drinking on heart disease and mortality among moderate drinkers 2Health News:Young children exposed to anesthesia multiple times show elevated rates of ADHD 2Health News:Science Shows How Massage Eases Sore Muscles 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: